Callio Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $187M
Overview
Targets rare neurological diseases with novel small molecules identified through phenotypic screening.
Rare Neurological DiseasesMitochondrial DisordersNeurodegeneration
Technology Platform
A phenotypic screening platform using patient-derived neurons to identify small molecules that rescue cellular dysfunction, independent of a pre-defined molecular target.
Funding History
1Total raised:$187M
Seed$187M
Opportunities
Potential for high pricing and expedited regulatory pathways due to focus on severe, rare diseases with no approved therapies.
Risk Factors
Phenotypic screening can lead to compounds with unknown or complex mechanisms, posing development and regulatory challenges.
Competitive Landscape
Occupies a specialized niche in rare neurology with a unique discovery approach, facing less direct competition but significant biological uncertainty.